The dry powder inhaler device market is projected to grow at a rate of 4.13% in terms of value, from USD 700.2 Million in 2022 to reach USD 964.5 Million by 2030. The growing demand for dry powder inhaler (DPI) devices can be mainly associated due to increasing incidences of asthma, lung disorders, and increasing pollution due to the high discharge of harmful chemicals.
Improvised efficiency of dry powder inhalers through advanced manufacturing processes and better results in comparison with alternative formulations and therapies is a driving factor that will aid market growth. Based on statistics, an increase in the aging population who are prone to or has a risk of respiratory infections will boost market growth. A significant cause of lung disorders in teenagers and adults is the addiction to nicotine. Increases in variations of hormones due to the changing lifestyle, which can trigger the need for having an addiction, are also significant factors stimulating market demand. Several brands of dry powder inhaler, including active and passive types, are available to provide medications for increasing pulmonary diseases across the globe. However, low awareness about the product and availability of substitutes with better resistance to moisture may create hindrances in the growth of the market in the forecast period
Request a Sample@ https://qyresearchmedical.com/sample/119046
The growing prevalence of diabetes in the US results in increased health care spending on diabetic treatment, and in turn, drives the market growth. According to a study published in 2016, it has been found that spending on diabetes rose from USD 37.00 billion in the year 1996 to USD 101.00 billion in the year 2013. The Center for Disease Control and Prevention (CDC) reports diabetes as the seventh leading cause of death among Americans as of 2022. Diabetes is no more limited to rich nations and is becoming most significantly in low-middle income countries. Diabetes has become one of four high priority Non-Communicable Diseases (NCDs) targeted for action by leaders across the globe.
North America dry powder inhaler market accounted for the largest share of 22.30% in 2018, which is driven due to the presence of world-class healthcare infrastructure with technologically advanced practice, a high number of people with respiratory problems, higher spending, strict guidelines and existence of leading industry players in the region. The US will boost the North America dry powder inhaler industry due to the increasing predominance of asthma and other respiratory diseases copulated with the growing geriatric population. The adoption of new technologies will further propel the growth of dry powder inhaler devices.
By product, capsule-based devices contributed to a larger market share of about 26.0% in 2022 and are expected to grow at a CAGR of 4.6% during the forecast period, due to the increase in a number of manufacturers offering vast products in the market and rise in preference of health care providers and patients for these devices.
Increase in incidence of respiratory disorders including asthma and chronic obstructive pulmonary diseases (COPD) increase in air pollution levels, especially in emerging countries and an increase in per capita health care spending are the major factors increasing demand and utilization of dry powder inhalers worldwide.
Multiple dry powder inhalers are popular among patients with respiratory diseases as an additional device for different places such as cars, homes, and job sites. With single-use dry powder inhalers, patients are allowed to carry the exact dose of inhalations needed in blister packs, which in turn promotes handling and comfort.
Single-dose accounted for the largest share of about 61.0% in 2022, due to the growing predominance of pulmonary and respiratory disorders. Elevated concentrations of toxic compounds and allergens in the air have given a lift to allergic conditions that cause asthma and other infections. This segment contributes majorly to market growth since it is affordable and developing nations with reasonable or low healthcare expenses can quickly adapt to these inhalers.
The rise in the number of prescriptions for dry powder inhalers by hospitals due to the growth rate of adoption shown by doctors boosts market growth. Hospitals held the largest market share in 2022 and are projected to witness a growth rate of 3.9% in the forecast period. The factors, including well-resourced diagnostic rooms, higher purchasing power, the existence of highly skilled healthcare professionals, and improved health coverage for hospital-based healthcare services from several private and group insurance plans, among others, are responsible for the high market share of hospitals.
Europe accounted for a market share of about 22.0% in 2022 and is estimated to reach USD 208.5 million by 2030. Lifestyle changes and rise in the occurrence of allergies and infections amongst the population has driven to an extended demand for dry powder inhalers in the overall market in Europe. Industrialization and excessive use of chemicals have further increased the occurrence of respiratory ailments in workers that have led to market development.
APAC is anticipated to have the fastest growth, due to a rapidly emerging medical infrastructure, increasing expenses on healthcare, and rising medical tourism in developing nations such as China and India in this region.
- An increase in variations of hormones due to the changing lifestyle, which can trigger the need for having an addiction, will show enhanced demand for dry powder inhaler industry growth.
- The asthma segment is valued at USD 205.1 million in 2018 and is estimated to reach USD 309.8 million by 2030 at a CAGR of 4.4% during the forecast period.
- The chronic obstructive pulmonary diseases (COPD) sector of the application segment accounts for a market share of 21.5% in 2018 and is estimated to reach USD 211.9 million by 2030 at a CAGR of 4.5%.
- IT accounts for the largest market share of 46.4% in 2018. The growth in this market segment is due to the availability of these inhalers in the pharmacies and the presence of strong business channels.
Key participants include 3M Company, Astrazeneca Plc., Chiesi Farmaceutici S.p.A., GlaxoSmithKline Plc, Novartis AG, Cipla Ltd., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, MannKind Corporation, and Vectura Group Plc.
The players operating in the market have undertaken a number of strategies related to the market in the period 2017-2022. Some of the key highlights are:
- In November 2017, 3M announced the launch of an intelligent inhaler, which has several beneficial properties to enhance outcomes by lessening patient errors and variability and giving data on use to healthcare providers and end-users.
The industry offers numerous growth opportunities. Thus, a number of startups providing innovative products and technologies have been entering the market. One such is TFF Pharmaceuticals, which in April 2018, raised USD 14.0 Million for an advance platform for dry powder inhalation.
Mergers and Acquisitions are an integral part of the industry. Along with the companies operating in the market, other key market players have also been entering the industry.
- In April 2022, Hovione Technology acquired the rights for the development and commercialization of an innovative multi-use blister-based, and ultra-affordable dry powder inhaler device (Papillon DPI) invented and patented by Dr. Klaus-Dieter Beller.
Reports and Data forecasts promising developments for increased adoption of dry powder inhaler device. According to industry experts, the use of products for asthma and COPD is garnering significant traction in the market. New companies entering the industry would emphasize designing and developing innovative products, thereby catering to the increasing requirement of end-users.
Segments covered in the report:
This report forecasts revenue growth at a global, regional & country level, and provides an analysis of the industry trends in each of the sub-segments from 2017 to 2030. The scope of the report can be defined as:
For the purpose of this study, Reports and Data have segmented the dry powder inhaler device market on the basis of product, application, type, end-user, and region:
Product Outlook (Revenue, USD Million; 2022-2030)
- Capsule based
- Blister based
- Reservoir/Cartridge based
Application Outlook (Revenue, USD Million; 2022-2030)
- Hereditary diseases
Type Outlook (Revenue, USD Million; 2022-2030)
- Single dose
End-User Outlook (Revenue, USD Million; 2022-2030)
- Hospitals and pharmacies
- Retail pharmacies
- Drug stores
Regional Outlook (Revenue, USD Million; 2022-2030)
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Saudi Arabia
- Rest of the Middle East and Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/119046/1500
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: